quantisnow
FeedTopReportsPricing
⌘K
Live feed
13:49:00·30d
PRRelease
Jazz Pharmaceuticals plc logo

American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education

JAZZ· Jazz Pharmaceuticals plc
Health Care
Original source

Companies

  • JAZZ
    Jazz Pharmaceuticals plc
    Health Care

Recent analyst ratings

  • Apr 10UpdateRaymond James$227.00
  • Feb 27UpdateBarclays$224.00
  • Nov 24UpdateUBS$188.00
  • Jul 15UpdateDeutsche Bank$152.00
  • Mar 7UpdateUBS$179.00
  • Feb 26UpdateCantor Fitzgerald-

Related

  • PR2d
    Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026
  • PR2d
    Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera® (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca® (lurbinectedin)
  • ANALYST13d
    Raymond James resumed coverage on Jazz Pharma with a new price target
  • PR14d
    Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting
  • INSIDER20d
    SEC Form 4 filed by Cozadd Bruce C
  • PR22d
    Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference
  • SEC22d
    SEC Form 144 filed by Jazz Pharmaceuticals plc
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Jazz Pharmaceuticals plc
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022